The brief · 6 May 2026
Today, AI is quietly making its way into diagnoses, customer scoring, and countless uses inside your bank that nobody's really keeping an eye on. And Brussels just bought itself two more years to write the rulebook.
ArteraAI Breast reads a biopsy and calculates recurrence risk for the most common form of breast cancer, hormone receptor-positive, HER2-negative. That should help oncologists decide who actually needs chemo after surgery, and who can safely skip it.
practitioners › FDA clearance granted May 6, 2026, the first tool of its kind built on multimodal digital pathology.
Artera →Forbes reports that treasury, payments and correspondent banking teams are heavily relying on AI tools that compliance has never signed off on. Regulators, meanwhile, are focused on the official deployments. The real risk is hiding in plain sight.
practitioners › Cited ratio: 4 ungoverned AI tools for every 1 under oversight, per Forbes (May 6, 2026).
Forbes →The European Council and Parliament have agreed on a package that eases the AI Act's compliance burden. Companies building or deploying high-risk AI systems get extra runway before enforcement kicks in. The deal also adds a targeted ban: 'nudification' apps that digitally strip clothing from photos without consent.
practitioners › Provisional agreement reached May 6, 2026 (AI Omnibus/Digital Omnibus): high-risk AI compliance deadline pushed from 2026 to December 2027.
www.consilium.europa.eu →